The present invention relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, which comprises a compound having a structure of Formula (III): ##STR00001## wherein R.sub.1 represents radioactive fluorine-18 (.sup.18F) or isotope fluorine-19 (.sup.19F), and R.sub.2 represents hydroxyamine (NH)OH. The hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention has the capability of selectively inhibiting histone deacetylase (HDAC) subtypes 8/6/3, and specifically targets to the focus of spinocerebellar ataxia with over-activation of HDAC. By labeling with the radioisotope fluorine-18, a positron emission tomography (PET) image is obtained with the hydroxamic acid-based contrast agent containing radioisotope fluorine-18, whereby spinocerebellar ataxia is effectively detected. Therefore, the hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention is potentially useful as a probe for early diagnosis and evaluation of the therapeutic effect of spinocerebellar ataxia.

According to embodiments described in the specification, a chemical process includes the steps of reacting a chemical reaction fluid including a solvent, 1,2-biaryl gem-dibromocyclopropane or 1,2-biphenyl-gem-dibromocyclopropane, and a metal salt including a silver tetrafluoroborate salt at low temperatures to make 1-phenyl-2-bromo indenes in a vessel that is capable of being closed.

According to embodiments described in the specification, a chemical process includes the steps of reacting a chemical reaction fluid including a solvent, 1,2-biaryl gem-dibromocyclopropane or 1,2-biphenyl-gem-dibromocyclopropane, and a metal salt including a silver tetrafluoroborate salt at low temperatures to make 1-phenyl-2-bromo indenes in a vessel that is capable of being closed.

The present invention includes DNP derivatives of formula (I) that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent. ##STR00001##

The present invention includes DNP derivatives of formula (I) that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent. ##STR00001##

The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.

Processes are described for the preparation of F-benzoxazinorifamycin I:

##STR00001##

and intermediates for conjugation with an antibody.

Processes are described for the preparation of F-benzoxazinorifamycin I:

##STR00001##

and intermediates for conjugation with an antibody.

The present invention relates to a Photo-caged MALDI Matrix Compound for use in a method of matrix-assisted laser desorption/ionization mass spectrometry, as well as to a sprayable liquid composition and a Photo-sensitive MALDI Matrix Composite, both comprising said Photo-caged MALDI Matrix Compound. Moreover, the present invention pertains to a matrix-assisted laser desorption/ionization mass spectrometry method involving the Photo-sensitive MALDI Matrix Composite and the Photo-caged MALDI Matrix Compound. Under a further aspect, the present invention pertains to a method of identifying for a given type of analyte and predetermined vacuum conditions a suitable Photo-caged MALDI Matrix Compound.

This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.